Advertisement

Response evaluation with 18F-FDG PET/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice

  • Silvia Taralli
  • Margherita Lorusso
  • Valentina Scolozzi
  • Valeria Masiello
  • Fabio Marazzi
  • Maria Lucia Calcagni
Original Article
  • 50 Downloads

Abstract

Objective

Palbociclib is a cyclin-dependent kinase 4/6 inhibitor recently approved for treatment in advanced or metastatic breast cancer (BC) patients. The use of 18F-FDG PET/CT for chemo/endocrine therapy response assessment in BC patients is well reported in the literature, but no studies have evaluated its role for assessing Palbociclib efficacy in clinical practice. Our study aimed to evaluate the potential role of 18F-FDG PET/CT in this setting.

Methods

In 12 metastatic BC patients (mean age = 62 ± 10 years) treated with Palbociclib plus endocrine therapy and who underwent a baseline and post-therapy 18F-FDG PET/CT, we retrospectively compared the Metabolic Response Evaluation (MRE, based on PET/CT) to the Standard Response Evaluation (SRE, based on clinico-laboratory and morphological data); we also assessed the influence of additional PET/CT information on the patients’ management.

Results

Compared to SRE, MRE increased the proportion of patients classified with progressive disease from 25 to 50% and differed from SRE in 8/12 patients: 3/8 shifted from stable disease or undetermined response to metabolic progression (more unfavorable category), 4/8 from stable disease to partial or complete metabolic response, and 1/8 from partial response to complete metabolic response (more favorable category). Additional PET/CT information led to a change in patients’ management in 3/12 (25%) patients.

Conclusion

In BC patients treated with Palbociclib, additional 18F-FDG PET/CT information seems clinically useful, with respect to personalized management, to early intercept patients who should discontinue Palbociclib because of progressive disease and to select patients requiring a strict monitoring of additional metabolic findings. Further studies are needed to confirm these preliminary results.

Keywords

18F-FDG PET/CT Breast cancer Palbociclib Response assessment 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have nothing to disclose.

References

  1. 1.
    Hoste G, Punie K, Wildiers H, Beuselinck B, Lefever I, Van Nieuwenhuysen E, et al. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer. Breast Cancer Res Treat. 2018.  https://doi.org/10.1007/s10549-018-4827-6.Google Scholar
  2. 2.
    Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016;34:3069–103.CrossRefGoogle Scholar
  3. 3.
  4. 4.
  5. 5.
    Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–19.CrossRefGoogle Scholar
  6. 6.
    Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–38.Google Scholar
  7. 7.
    Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 2005;48:2388–406.CrossRefGoogle Scholar
  8. 8.
    Mangini NS, Wesolowski R, Ramaswamy B, Lustberg MB, Berger MJ. Palbociclib: a novel cyclin-dependent kinase inhibitor for hormone receptor–positive advanced breast cancer. Ann Pharmacother. 2015;49:1252–60.CrossRefGoogle Scholar
  9. 9.
    Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018;29:669–80.CrossRefGoogle Scholar
  10. 10.
    Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):41–54.CrossRefGoogle Scholar
  11. 11.
    Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med. 2009;50(Suppl 1):97S–105S.CrossRefGoogle Scholar
  12. 12.
    Evangelista L, Cervino AR. Nuclear imaging and early breast cancer detection. Curr Radiopharm. 2014;7:29–35.CrossRefGoogle Scholar
  13. 13.
    Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, et al. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist. 2015;20:94–104.CrossRefGoogle Scholar
  14. 14.
    Yeruva SLH, Javadi MS, Stearns V. Complete response to single-agent palbociclib in metastatic breast cancer: a case report. Clin Breast Cancer. 2018;18:e277–80.CrossRefGoogle Scholar
  15. 15.
    Dhakal A, Matthews CM, Levine EG, Salerno KE, Zhang F, Takabe K, et al. Efficacy of palbociclib combinations in hormone receptor-positive metastatic breast cancer patients after prior everolimus treatment. Clin Breast Cancer. 2018.  https://doi.org/10.1016/j.clbc.2018.04.015.Google Scholar
  16. 16.
    Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82.CrossRefGoogle Scholar
  17. 17.
    Berger ML, Lipset C, Gutteridge A, Axelsen K, Subedi P, Madigan D. Optimizing the leveraging of real-world data to improve the development and use of medicines. Value Health. 2015;18:127–30.CrossRefGoogle Scholar
  18. 18.
    Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101–11.CrossRefGoogle Scholar
  19. 19.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefGoogle Scholar
  20. 20.
    Cook GJ, Azad GK, Goh V. Imaging bone metastases in breast cancer: staging and response assessment. J Nucl Med. 2016;57(Suppl 1):27S–33S.CrossRefGoogle Scholar
  21. 21.
    Avril S, Muzic RF Jr, Plecha D, Traughber BJ, Vinayak S, Avril N. 18F-FDG PET/CT for monitoring of treatment response in breast cancer. J Nucl Med. 2016;57(Suppl 1):34S-9S.Google Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2018

Authors and Affiliations

  • Silvia Taralli
    • 1
  • Margherita Lorusso
    • 1
  • Valentina Scolozzi
    • 1
    • 2
  • Valeria Masiello
    • 3
  • Fabio Marazzi
    • 3
  • Maria Lucia Calcagni
    • 1
    • 2
  1. 1.Nuclear Medicine UnitFondazione Policlinico Universitario Agostino Gemelli IRCCSRomeItaly
  2. 2.Nuclear Medicine InstituteUniversità Cattolica del Sacro CuoreRomeItaly
  3. 3.Radiation Oncology UnitFondazione Policlinico Universitario Agostino Gemelli IRCCSRomeItaly

Personalised recommendations